Oncology

Latest News

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com
COA 2025: Insight, Innovation, and Independent Strength

May 5th 2025

The 2025 Community Oncology Conference empowered attendees with insights on advocacy, innovation, and practical strategies for enhancing community cancer care.

COA logo | Image Credit: © Amy Kinnamon
Community Oncology Reacts to Trump's Drug Pricing Executive Order

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com
5 Things You Should Know About Skin Cancer

May 2nd 2025

stethoscopewithcompass | Image Credit: © Talaj-stock.adobe.com
Patient Navigation Is Nonnegotiable in Cancer Care

May 1st 2025

Liver cancer - Sebastian Kaulitzki - stock.adobe.com.jpg
Elevated HLA-G Seen in HCC Driven by Viral Infections, Fatty Liver

May 1st 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

This Week in Managed Care: February 23, 2018
February 23rd 2018

This Week in Managed Care: February 23, 2018

This week, the top managed care stories included the Trump administration proposed extending the duration of short-term health plans; a report found that CAR T-cell therapies are worth their high price tags; the new issue of Evidence-Based Oncology® examined current issues in immunotherapy.
AJMC® in the Press, February 23, 2018
February 23rd 2018

AJMC® in the Press, February 23, 2018

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Liquid Biopsy Can Predict Outcomes in Patients With Triple-Negative Breast Cancer, Researchers Say
February 22nd 2018

Liquid Biopsy Can Predict Outcomes in Patients With Triple-Negative Breast Cancer, Researchers Say

Jaime Rosenberg
Cell-free DNA derived from liquid biopsy offers the potential for minimally invasive genome-wide profiling of tumor alterations without tumor biopsy and can predict patient survival outcomes for patients with metastatic triple-negative breast cancer, according to a team of researchers.
Site Logo
February 22nd 2018

With Approval of CAR T-Cell Therapy Comes the Next Challenge: Payer Coverage

Mary Caffrey
CAR T- cell therapies are among the most expensive ever invented. For now, there’s a lot of uncertainty, as both government and commercial insurers, and a handful of the nation’s leading cancer centers, navigate a reimbursement structure that truly has no precedent.
Site Logo
February 22nd 2018

Diminished Employment Participation After Breast Cancer Linked to Race and Insurance Status

Kelly Davio
African American patients and uninsured patients are more likely to have diminished employment participation 2 years after being cancer free than are those with no history of cancer, according to new research published in Cancer.
ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit
February 21st 2018

ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit

Jaime Rosenberg
CAR T-cell therapies tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead) may come with hefty price tags, but the cost-effectiveness of both therapies fell below or within commonly cited thresholds of $50,000 to $150,000 per quality-adjusted life years, according to a report by the Institute for Clinical and Economic Review.
What We're Reading: Cost of Healthcare Bills; Albertsons Buying Rite Aid; Pediatric Cancer Therapies
February 21st 2018

What We're Reading: Cost of Healthcare Bills; Albertsons Buying Rite Aid; Pediatric Cancer Therapies

AJMC Staff
Research analyzes the cost of processing healthcare bills; supermarket operator Albertsons will buy drugstore chain Rite Aid; a review of phase 1 clinical trials finds just 1 in 10 children with cancer see improvements.
Second-Line Nilotinib May Enable Patients With CML to Achieve Treatment-Free Remission
February 21st 2018

Second-Line Nilotinib May Enable Patients With CML to Achieve Treatment-Free Remission

Laura Joszt, MA
Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response can maintain treatment-free remission for at least 48 weeks after using second-line nilotinib, according to a new study published in Annals of Internal Medicine.
Site Logo
February 21st 2018

Provocative Questions, Better Biomarkers, and the Prospect of Triple Therapy: A Conversation With NYU's Jeffrey S. Weber, MD, PhD

Mary Caffrey
Ipililumumab's role in treating melanoma will change, as the immunotherapy will likely become part of different combinations than we see today.
Site Logo
February 21st 2018

Recent Approval of Trastuzumab Biosimilar, Ogivri, Has Implications for Patients and Industry

Samantha DiGrande
Last year's approval of trastuzumab biosimilar, Ogivri, will be the first competitor to blockbuster drug, Herceptin, for the treatment of HER2-positive breast cancer since its discovery.
Site Logo
February 21st 2018

The Clinical Trial and the Patient's Voice: "I'm Extremely Lucky to Be Alive"

Mary Caffrey
Two stories--of taking part in clinical trials, and of serving as a voice for patients among scientists who run them--highlight how the advances in cancer are built on the trust between those living with the disease and the clinicians on the frontiers of care.
Dr Adam Brufsky Discusses Value Coordinates of Breast Cancer Care
February 20th 2018

Dr Adam Brufsky Discusses Value Coordinates of Breast Cancer Care

Adam M. Brufsky, MD, PhD, co-director of the Comprehensive Breast Cancer Center at University of Pittsburgh, notes important value coordinates of breast cancer care.
Site Logo
February 20th 2018

Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer

Dave Nellesen, PhD Katerine Dea, MSc Annie Guerin, MSc Kenneth W. Culver, MD Alex Mutebi, PhD Anand Dalal, MBA, BSPharm
This review assesses the current molecular testing landscape for non–small-cell lung cancer in the United States.
Cancer Survivors Manage Fatigue With Placebo Pills
February 19th 2018

Cancer Survivors Manage Fatigue With Placebo Pills

Kaitlynn Ely
Cancer survivors may be able to manage the extreme fatigue they experience after treatment by knowingly taking a placebo pill, according to researchers at University of Alabama at Birmingham and Harvard Medical School.
USPSTF Recommends Against Screening for Ovarian Cancer in Asymptomatic Women
February 18th 2018

USPSTF Recommends Against Screening for Ovarian Cancer in Asymptomatic Women

Jaime Rosenberg
The US Preventive Services Task Force recommends against screening for ovarian cancer in asymptomatic women who are not known to have a high-risk hereditary cancer syndrome because evidence shows that screening does not reduce ovarian cancer mortality.
Site Logo
February 17th 2018

Variation in Markups on Outpatient Oncology Services in the United States

Angela Park Tim Xu, MD, MPP Michael Poku, MD, MBA James Taylor, MBBChir, MPH, MRCS(Eng) Martin A. Makary, MD, MPH
Charges for oncology services vary widely across hospitals and impose financial burdens. Further legislation is needed to address disparities in access to high-quality cancer care.
Study Finds Merkel Cell Carcinoma Incidence Has Increased Since 2000
February 17th 2018

Study Finds Merkel Cell Carcinoma Incidence Has Increased Since 2000

Kaitlynn Ely
Merkel cell carcinoma (MCC) is a rare disease, but it's getting less rare. Study results presented at the American Academy of Dermatology 2018 Annual Meeting found that cases of MCC increased 95% between 2000 and 2013
Site Logo
February 17th 2018

eAppendix

Dave Nellesen, PhD Katerine Dea, MSc Annie Guerin, MSc Kenneth W. Culver, MD Alex Mutebi, PhD Anand Dalal, MBA, BSPharm
Site Logo
February 16th 2018

Development of a Tailored Survey to Evaluate a Patient-Centered Initiative

Marcy Winget, PhD Farnoosh Haji-Sheikhi, MS Steve M. Asch, MD, MPH
We developed short patient experience surveys that were sensitive to our broad quality initiative, were meaningful and acceptable to patients, and had good response rates.
AJMC® in the Press, February 16, 2018
February 16th 2018

AJMC® in the Press, February 16, 2018

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Roche Acquires Flatiron Health for $1.9 Billion
February 16th 2018

Roche Acquires Flatiron Health for $1.9 Billion

Mary Caffrey
Flatiron Health expects to maintain its current business model in the transaction.
Nat Turner on the Main Barriers for Flatiron Health in Providing Care in Oncology
February 16th 2018

Nat Turner on the Main Barriers for Flatiron Health in Providing Care in Oncology

Nat Turner, co-founder and CEO of Flatiron Health, says that clinical research accessibility is one of the biggest barriers in oncology care that Flatiron Health is working to remove.
Site Logo
February 15th 2018

Pricing of Monoclonal Antibody Therapies: Higher If Used for Cancer?

Inmaculada Hernandez, PharmD, PhD Samuel W. Bott, BS Anish S. Patel, BS Collin G. Wolf, BS Alexa R. Hospodar, BS Shivani Sampathkumar, BS William H. Shrank, MD, MSHS
The annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states.
Family History Associated With Breast Cancer Risk for Women 65 and Older
February 15th 2018

Family History Associated With Breast Cancer Risk for Women 65 and Older

Jaime Rosenberg
First-degree family history was associated with an increased risk of breast cancer among women aged 65 and older, and risk associated with family history was not significantly modified by breast density, according to a study in JAMA Oncology.
FDA Approves Apalutamide, First Treatment for Nonmetastatic Castration-Resistant Prostate Cancer
February 15th 2018

FDA Approves Apalutamide, First Treatment for Nonmetastatic Castration-Resistant Prostate Cancer

Laura Joszt, MA
FDA has approved apalutamide, the first treatment for nonmetastatic castration-resistant prostate cancer, based on results from a phase 3 study that showed the drug reduced the risk of metastasis or death by 72% and improved median metastasis-free survival by more than 2 years.
Site Logo
February 15th 2018

ASCO and NCCN Release Guidelines on Managing Immunotherapy-Related Toxicities

Kelly Davio
The American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) have developed new guidelines on managing immune checkpoint inhibitor-related toxicities.
Site Logo
February 14th 2018

Pembrolizumab Associated With Increased Overall Survival in Patients With Urothelial Cancer

Jaime Rosenberg
There is a greater overall survival benefit for patients with recurrent urothelial cancer being treated with pembrolizumab versus chemotherapy, according to long-term results of the KEYNOTE-045 trial.
ASCO Review Finds Clinical Pathway Programs Adhere to Guidelines
February 13th 2018

ASCO Review Finds Clinical Pathway Programs Adhere to Guidelines

Samantha DiGrande
Last week, the American Society of Clinical Oncology (ASCO) published its review of the leading oncology pathway vendors in the United States in the Journal of Oncology Practice. The report found that overall, the prominent commercial pathway programs in the United States are aligned with ASCO’s evaluation criteria.
Kentucky's Medicaid Expansion Associated With Improved Breast Cancer Care
February 13th 2018

Kentucky's Medicaid Expansion Associated With Improved Breast Cancer Care

Jaime Rosenberg
Medicaid expansion in Kentucky led to an increase of screening mammograms, screening coverage, and breast-conserving surgery for women aged 20 to 64 with breast cancer, according to a study published in the Journal of the American College of Surgeons. However, the study also showed that time from diagnosis to operation increased post expansion and time from operation to chemotherapy remained unchanged.
Dr Roger Brito Discusses Practitioners Taking on 2-Sided Risk
February 12th 2018

Dr Roger Brito Discusses Practitioners Taking on 2-Sided Risk

We want to know all sides of the 2-risk model, like with any challenge or strategy, said Roger Brito, DO, national director for oncology, Aetna.
<1
...
545556575859606162
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo